Cargando…
中国人群肺鳞癌患者免疫治疗疗效及不良反应观察
BACKGROUND AND OBJECTIVE: Immune checkpoint inhibitors (ICIs) improved survival of partial patients with lung squamous cell carcinoma (LUSC). However, it was still insufficient of data in older patients. This study aimed to investigate the efficacy and toxicity of immunotherapy in patients with LUSC...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346147/ https://www.ncbi.nlm.nih.gov/pubmed/35899455 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.36 |
Ejemplares similares
-
OLC1在肺鳞癌组织中的过表达与患者的不良预后相关
Publicado: (2017) -
厄洛替尼治疗34例肺鳞癌患者的疗效观察
Publicado: (2016) -
肺癌伴肺裂发育不良应用无肺裂肺叶切除法疗效观察
Publicado: (2013) -
2010年-2015年SEER数据库肺腺鳞癌患者临床特征及预后分析
Publicado: (2018) -
阿法替尼一线治疗5例晚期肺腺癌患者的不良反应分析及相关文献回顾
Publicado: (2014)